Humacyte (HUMA) and Pluristyx announced an expanded partnership. Pluristyx makes and sells PluriBank iPSC lines as part of their tools, technologies, and services to support the development of cellular therapies, and is currently performing gene editing of PluriBank cells for Humacyte’s use in developing its investigational BioVascular Pancreas, designed for the potential treatment of insulin-dependent diabetes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Humacyte announces planned IND filing in 2025 for sdATEV for CABG
- HUMA Lawsuit Alert! Class Action Against Humacyte, Inc.
- Humacyte provides update on commerical launch, pricing of Symvess
- Hertz Global Holdings call volume above normal and directionally bullish
- Humacyte price target raised to $17 from $15 at Benchmark